REGULATORY · COMPETITIVE · CHINA
China halts Sun Pharma rivastigmine sales
Change
On January 26, 2026, China's National Medical Products Administration ordered a halt to the import, sale, and use of Sun Pharmaceutical Industries' rivastigmine hydrogen tartrate capsules.
Why it matters
A remote inspection identified shortcomings in the company's production processes, including failures in contamination prevention and in the quality management department’s fulfillment of duties. The regulator's action covers rivastigmine hydrogen tartrate capsules and prohibits their importation, commercial sale, and clinical use within China. The ban was posted on January 26, 2026. Sun Pharmaceutical Industries did not provide a comment when contacted.
Implications
- · Importers and customs agents in China must stop bringing Sun Pharma's rivastigmine hydrogen tartrate capsules into the country.
- · Distributors, pharmacies, and hospitals in China must cease selling and supplying that specific rivastigmine formulation.
- · Clinicians and healthcare facilities in China must stop administering that rivastigmine product to patients.
- · Sun Pharmaceutical Industries is barred from commercial distribution of the specified rivastigmine capsules in China.
Who is affected
- · Sun Pharmaceutical Industries (manufacturer)
- · Importers and distributors of pharmaceuticals in China
- · Hospitals, pharmacies, and clinicians in China
- · Regulatory compliance teams for pharmaceutical import and distribution
What to watch
- · Enforcement effective date: January 26, 2026
Source
Topics
Law & Public Safety Regulatory Actions Health & Medicine Pharma & Biotech Healthcare Systems